1. A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising: (a) administering a drug providing 6-thioguanine to a subject having said immune-mediated gastrointestinal disorder; and (b) determining the level of 6-thioguanine in said subject having said immune-mediated gastrointestinal disorder, wherein the level of 6-thioguanine less than about 230 pmol per 8 × 10 8 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject and wherein the level of 6-thioguanine greater than about 400 pmol per 8 × 10 8 red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject.
(emphases added).
The key holding in the case starts with the long-established premise that certain discoveries such as laws of nature, naturally occurring phenomena, mathematical algorithms and abstract ideas are not themselves eligible for patenting (these exceptions are lumped together by the Court as "laws of nature") 3 . The holding goes on to state that patent claims that feature applications of such discoveries are likewise ineligible for patent unless they include certain additional features. Exactly what additional features might be required was not clearly elucidated by the Court, but certain trends can be inferred. For example, the opinion clearly favors the inclusion of "postsolution activity" in a claim; that is, inclusion of an action step (e.g., administering a drug) in the claim after the recitation of the "law of nature, " as opposed to "wherein" clauses such as in claim 1 of the '623 patent 4 . Also implicit in the opinion is the possibility that recitation of specific "pre-solution activity, " that is, a specific assay by which to measure the "law of nature, " as opposed to a generalized requirement to "determine" or "measure, " again as in claim 1 of the '623 patent, may confer eligibility 5 .
Patented innovations in the areas of diagnostics, biomarkers and personalized medicine have customarily been claimed as a correlation between a given mutation, phenotype or gene expression profile and a diagnosis, prognosis, actual or potential responsiveness to a drug, or other assessment of a subject or patient (e.g., a combination of a "determining" step and recitation of the correlation as a "wherein" clause, similar to the claims found ineligible in Prometheus, and exemplified above). This well-established, claim-drafting standard has long been allowed by examiners at the United States Patent and Trademark Office (USPTO), provided that the statutory requirements of novelty, non obviousness, written description and enablement were met. Similarly, claims of this format have been successfully licensed and successfully asserted against potential infringers. Prometheus puts into doubt the patent eligibility of granted claims written in this format.
Despite considerable speculation about the potential impact of Prometheus, to our knowledge, no studies have attempted to quantify the actual effect of the decision on existing intellectual property (IP) rights in the diagnostic, biomarker and personalized medicine areas. Accordingly, we have conducted a retrospective analysis of granted US patent claims in these subject matter areas. Our results reveal real and extensive vulnerability for previously established IP rights. This is perhaps good news for some parties, such as laboratories burdened by the existence of patent rights in gene and biomarker diagnostics. On the other hand, the outlook for innovators in these areas is discouraging, but perhaps not fatal. We discuss potential strategies for damage control for patent holders and patent applicants.
Data mining and analysis
Our retrospective analysis was done on a representative data set of US patents granted after 1992. Under 35 USC §154, a patent term begins on the date on which the patent issues and ends 20 years from the earliest nonprovisional filing date of the application. Patents that issued before 1992 were filtered out from our data set, since all pre-1992 patents should have expired by now 6 . The data set was the result of a search conducted on the Thomson Innovation US Granted Patent commercial database (Supplementary Methods, Section I), using search terms based on the language used in the claims at issue in Prometheus and other relevant case law, and terms commonly found in method or process patent claims in medicine, biomedicine or biotech.
The resulting 10,293 records of granted patent were subsequently curated to yield a nonredundant set of records with IPC (International Patent Classification) codes in the A61 and C12 classes. The curated data set comprised 2,218 granted patent records (Supplementary Methods, Section III).
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Of the approximately 1,180 claims we directly analyzed, only 15 contained a postsolution activity step. The types of activities were primarily treatment steps, for example, 'administering drug X to a patient' (specific), or 'determining a chemotherapeutic regimen for treating cancer in the individual based on the level of biomarker Y' (nonspecific). The dearth of claims with post-solution activity stems from long-established best practices for drafting method claims, practices that are about to change.
Whereas claims reciting post-solution activity may be deemed patent eligible, the courts have imposed another layer of complexity that may render such claims virtually unenforceable, referred to as the "split-infringement" problem 7 . In two recent cases related to interactive web-based applications, the Court of Appeals for the Federal Circuit determined that a claim is not infringed unless every step of the claim is performed by a single party, or by two parties that are in agency or are contractually obligated to perform the claim together 8, 9 . Both cases were heard by three-judge panels, and both are currently being reheard by the entire court. The panel decisions thus may be overruled.
Although these cases had nothing to do with biotech, the split-infringement problem poses a real dilemma for drafters of diagnostic, biomarker or personalized medicine-related claims reciting post-solution activity. For example, in claims with the general format 3 or 4 ( Fig. 1) , the 'determining' step would likely be performed by a clinical laboratory, whereas the 'treating' or 'selecting a therapy' post-solution activity step would likely be performed by a healthcare professional such as a physician. Where the claim as a whole is performed by two or more different, unrelated parties, under the current case law precedent a court would find the claims to be unenforceable because no single party infringes the claim. Of the 15 claims analyzed in our study that recite postsolution activity, all have the potential of unenforceability due to split infringement.
Strategies for damage control
Until further clarification is provided by the USPTO and the courts, patent applicants pursuing claims that include a law of nature would be wise to present a wide variety of claims with varying scope and varying focus. Finding support for Prometheus-compliant claims in existing application disclosures could prove to be challenging in some instances. Going forward, however, applications to new inventions can be drafted to include support for a broad spectrum of claim formats.
The vast majority of claims reviewed in our study (98.7%) failed to include any sort of postsolution activity (Fig. 1 and Supplementary  Table 4 ). Of those, however, about 20.1% recited fairly specific assays to determine the "law of nature, " which may support eligibility under certain interpretations of the holding, even in the absence of post-solution activity. The few claims containing post-solution activity limitations (about 1.4%) are fairly evenly divided between those that recite specific actions, and those that recite more generalized actions.
Impact on existing patent rights
This retrospective analysis confirms that a considerable number of granted claims in the biomarker, diagnostics and personalized medicine fields may no longer be patent eligible in view of the holding in Prometheus. As a result, many of these granted patents will be vulnerable to validity challenges if asserted against potential infringers, and existing licensees may seek to challenge existing agreements or renegotiate the terms of licensing agreements, arguing that the licensed patents are no longer patent eligible. In short, the impact of the Prometheus holding on existing property rights in a broad sector of the biotech industry is real and potentially profound. Table 2) . Subsequent analyses were limited to an ~1,180-record subset of the curated data set corresponding to US Patent Class 435 (molecular biology and microbiology comprising measuring or testing processes; Supplementary Table 3 and Supplementary Fig. 4 show the ten most common Class 435 subclasses in the curated data set). We analyzed the first granted claim in each patent's claim set. To quantify the extent of potential vulnerabilities related to Prometheus, we manually analyzed and classified the claims into four categories: (1) claims reciting no, or generalized nonspecific, 'pre-solution activity' and no 'post-solution activity'; (2) claims reciting specific 'pre-solution activity' and no 'post-solution activity'; (3) claims with generalized, nonspecific, 'postsolution activity'; and (4) claims with specific 'post-solution activity' (Fig. 1) . determining the presence of gene mutation X in a nucleic acid sample, and selecting, based on the presence of gene mutation X, a therapy that included the administration of drug Y PaT e n T S npg reciting laws of nature are already appearing. District courts will not be far behind. The holding, when combined with the split-infringement problem, will require innovators in diagnostics, biomarkers and personalized medicine, along with their patent counsel, to rethink well-established strategies for obtaining and enforcing patent rights. For currently pending applications, action will be required very soon.
Just like Zeus condemned Prometheus to endless martyrdom for having stolen fire and given it to humans, the Supreme Court has punished innovators (or, depending whom you talk to, overzealous claim drafters) who have attempted to capture a law of nature for the good (or detriment) of mankind.
applications must have been filed, however, before the parent patent proceeded to grant. Under 35 USC §120, a continuation or divisional application can only be filed if it is co-pending with a parent application 12 .
For granted US patents in which no patent family members remain pending, repair of claims to be in compliance with the Prometheus holding may be possible through reissue. Under the US Patent Act, a patentee may request reissue of a granted patent which "through error without any deceptive intention, is deemed wholly or partly inoperative or invalid" 13 . Under the reissue rules, a patentee must pay a fee and make a detailed statement of why the patent is inoperable or invalid 14 . A change in the law such as that dictated in Prometheus would certainly qualify as such a reason. During reissue prosecution, claims reciting post-solution activity and/or specific assays or techniques for measuring the law of nature recited in the claim can be presented for examination. Importantly, the existing patent specification would have to support any claim amendments, as the patent cannot be amended to include new matter. Other risks, such as potential third-party protests or submissions, intervening rights and potential litigation estoppels, must also be carefully considered 15 .
Prometheus has the potential to extend far beyond innovations in the diagnostics, biomarker and personalized medicine spaces to patents in other areas of biotech and indeed, to other technology areas such as software and business methods. For example, after deciding Prometheus, the US Supreme Court immediately remanded Assn. for Molecular Pathology et al. v . Myriad et al. 16 for further consideration by the Federal Circuit. The claims at risk in Myriad include diagnostic claims (already held patent-ineligible by the Federal Circuit), and also composition claims to isolated DNA molecules comprising the BRCA1 or BRCA2 mutations, and claims to methods of screening potential drug candidates comprising testing the candidates on cells transformed with DNA containing the mutations. On remand, the Federal Circuit will consider whether the Prometheus decision is applicable to the isolated DNA and drug-screening claims. A decision is not expected until later in the year.
Conclusions
Prometheus is a game changer. The USPTO has already provided guidance for examiners 17 in view of the decision, and rejections of claims What sorts of claim formats? Any and all formats which might be construed to be an 'unconventional' application of a law of nature. Probably the clearest guidance by the Supreme Court is to include significant post-solution activity in claims, for example, as shown in sample claims 3 and 4 in Fig. 1 . The Court cited precedential cases in which significant postsolution activity was found (patent-eligible) 10 and in which significant post-solution activity was not found (patent ineligible) 11 , but did not provide details as to how significant the postsolution activity must be, or indeed, whether post-solution activity would be required. The Court noted that the claims-in-suit only ask a physician to "draw an inference" from the recited correlation rather than requiring a physician to act on the information by, for example, adjusting the dose. In other words, after a correlation is established between a diagnosis, prognosis or disease, include a step in the claim that requires an action in response to the correlation. As a further challenge, innovators and their patent counsel will need to carefully identify the parties likely to practice the invention, and then draft claims that would be practiced by a single party in order to avoid the splitinfringement problem.
Further guidance by the Supreme Court: include claims reciting a specific assay or technique for measuring a law of nature. The Court noted that whereas the step of 'determining' the metabolite levels in Prometheus's claims currently requires obtaining a blood sample from a patient and assaying for metabolites in the sample, in the future such a determination might be accomplished without any need for sample procurement and processing. Thus, the determining step, according to the Court, provided no meaningful limitation to the law of nature. In view of the Court's discussion, a claim that includes a more specific assay (e.g., step (a) in sample claim 2 (Fig. 1) ) might be deemed patent-eligible. Clarification by the courts and the USPTO will be needed to determine the veracity of this strategy.
Although any number of creative claiming strategies can and should be pursued in currently pending and future patent applications, no easy strategies exist to repair claims in granted patents, such as those examined in this study. In many cases, granted patents may be part of a family that includes still-pending continuation or divisional applications into which claims more likely to be patent-eligible under Prometheus can be added. Continuation or divisional PaT e n T S npg
